Zura Bio Limited (Nasdaq: ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated ...

Patients with SSc were linked to an increased risk for hematological malignancies, specifically B-cell malignancies.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated ...

Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing ...

Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt ...

A new antifibrotic option for patients living with idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated ...

A rare condition called Eosinophilic Fasciitis caused a 42-year-old engineer severe pain and stiffness. Doctors identified ...

Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19 ...

Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate ...

Under normal conditions, cytokines aid in pathogen recognition and elimination while contributing to immune system ...

NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today reported the results of an international collaborative ...